REG - Arecor Therapeutics - Arecor announces launch of Ogluo® in Netherlands

Arecor TherapeuticsAnnouncement

29/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc8614Ea&default-theme=true

RNS Number : 8614E  Arecor Therapeutics PLC  29 February 2024

 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS

-      Launch builds on continued pan-European commercial roll-out
following earlier launches in Denmark, Norway, Austria, Germany and the UK

 

Cambridge, UK, 29 February 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
notes the announcement today from subsidiary company, Tetris Pharma Ltd, that
Ogluo® (glucagon prefilled autoinjector pen) has been launched in the
Netherlands as a treatment for severe hypoglycaemia in adults, adolescents,
and children aged two years and over living with diabetes mellitus.

Ogluo® has been launched in the Netherlands by Goodlife, under the previously
announced, existing commercialisation agreement between Tetris Pharma Ltd and
Goodlife, which has established Goodlife as the sole partner for the import,
marketing and distribution of the product in the BeNeLux region.

See full Tetris Pharma announcement below:

 

Ogluo® launches in the Netherlands

 

Availability of glucagon prefilled autoinjector pen in first BeNeLux country,
in partnership with Goodlife, further expands reach of Ogluo® across Europe

Continued momentum in pan European roll-out following earlier launches in
Denmark, Norway, Austria, Germany and the UK

 

29 February 2024 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a
subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC),
today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in
the Netherlands as a treatment for severe hypoglycaemia in adults,
adolescents, and children aged two years and over living with diabetes
mellitus.

The launch is part of an existing exclusive commercialisation agreement
between Tetris Pharma Ltd and Goodlife, announced in September 2023, which
established Goodlife as the sole partner for the import, marketing and
distribution of the product in the BeNeLux region.

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an
auto-injector for patients within the licenced indication living with diabetes
suffering from severe hypoglycaemia. Today's launch builds on the continued
roll-out of Ogluo® across key European markets, including, Denmark, Norway,
Austria, Germany and the UK, as part of Tetris Pharma's pan-European
commercialisation programme.

Dr. Helen Parris, Senior Vice President, Commercial and General Manager of
Tetris Pharma, commented: "The launch of Ogluo® in the Netherlands presents a
significant milestone for Tetris Pharma, strengthening the commercial reach
and pan-European presence of this important product and giving patients living
with diabetes who may experience severe hypoglycaemia, a treatment option to
tackle those events. Goodlife's leading know-how and expertise of regional
market dynamics make them an ideal partner to support with the roll-out of
Ogluo® in the BeNeLux region. We look forward to continuing to expand our
reach within Europe to bring this treatment option to people living with
diabetes."

 

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage
specialty pharmaceutical company with expertise in registering, marketing,
sales and the distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and growing
sales. Having secured distribution rights for already licensed products across
Europe, we have a portfolio of niche injectable products including Ogluo®, a
ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate
with partners to provide patients with effective treatments and quality
healthcare by ensuring we deliver accountability, partnership and performance.
For further information, please visit www.tetrispharma.com
(http://www.tetrispharma.com) .

 

Goodlife is a privately owned pharmaceutical company with a focus on The
Netherlands, Belgium and Luxembourg. Goodlife believes that every patient
deserves excellent care that matches their individual needs, even if those
needs deviate from the norm.  With this in mind, we strive for customization
every day, by providing unique medicines, medical devices, dietary supplements
and supportive tools for individual patients in the BeNeLux. For more
information, please visit www.goodlifepharma.com
(http://www.goodlifepharma.com) .

 

 

-ENDS-

 

 

 

 

For more information, please contact:

 

 

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Financial Advisor)
 Nigel Barnes, Satheesh Nadarajah                Tel: +44 (0)203 705 9321

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio. For further details
please see our website, www.arecor.com (http://www.arecor.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLMZGZZRRLGDZM